Biogen Idec Seeks Oncology Pipeline Boost Through Acquisition
This article was originally published in The Pink Sheet Daily
Executive Summary
Merger with Conforma Therapeutics, valued at up to $250 mil., brings Biogen Idec a stable of developmental heat shock protein inhibitors.
You may also be interested in...
Pharmion Boosts Oncology Pipeline With Cabrellis Acquisition
Purchase gives Pharmion North American and EU rights to the novel anthracycline amrubicin, currently marketed in Japan for both small and non-small cell lung cancers.
Pharmion Boosts Oncology Pipeline With Cabrellis Acquisition
Purchase gives Pharmion North American and EU rights to the novel anthracycline amrubicin, currently marketed in Japan for both small and non-small cell lung cancers.
MedImmune Bolsters Oncology Pipeline Under Agreement With Infinity
Deal for development of two candidates could be worth up to half a billion dollars.